Krainer Adrian R. 4

What Happened Adrian R. Krainer, a director of Stoke Therapeutics, sold 33,243 shares on March 10, 2026. The reported weighted-average sale price was $39.74 per share for total proceeds of $1,320,964. The filing lists the transaction as an open-market or private sale (code S), which is generally a routine insider sale rather than a purchase signal.

Key Details

• Transaction date: March 10, 2026; Form 4 filed March 12, 2026 (appears timely — Form 4s are due within two business days).
• Price: weighted-average $39.74; individual sale prices ranged from $39.50 to $40.11 per share.
• Shares sold: 33,243; reported proceeds: $1,320,964.
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Footnotes: (1) Sale executed under a Rule 10b5-1 trading plan adopted August 15, 2025. (2) Reported price is a weighted average; the filer will provide a per-price breakdown on request.

Context This was a sale executed under a pre-established 10b5-1 plan, which allows insiders to sell according to a preset schedule and is typically viewed as routine. Sales do not necessarily indicate negative company-specific information; purchases are generally more informative about insider sentiment.